1
1
1
1
2
2
1
1
3
3
2019
2001
University (8)Hospital (4)Research Institution (3)
1 - 8 of 8
Sort by
Publication
ID31685512Published Date2019-11-03JournalBMJ open, 2019-11-03, Volume 9
With the emergence of Zika virus (ZIKV) disease in Central and South America in the mid-2010s and recognition of the teratogenic effects of congenital exposure to ZIKV, there has been a substantial increase in new research published on ZIKV. Our objective is to synthesise the literature on health outcomes associated with ZIKV infection in humans.We conducted a systematic review (SR) of SRs following Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. We searched MED…
Publication
ID31575578Published Date2019-09-30JournalBMJ open, 2019-09-30, Volume 9
An increasing proportion of fetuses are exposed to antenatal corticosteroids (ACS). Despite their immediate beneficial effects, the long-term safety of ACS has been an ongoing source of concern. In the current study, we assessed the likelihood of neurodevelopmental problems among term infants exposed to ACS earlier in pregnancy compared with non-exposed term infants.Retrospective cohort study (2006-2011). Median duration of follow-up was 7.8 (IQR 6.4-9.2) years.Population-based study, Ontario…
Publication
ID27435163Published Date2016-07-19JournalBMC pregnancy and childbirth, 2016-07-19, Volume 16
The incidence of type 2 diabetes in pregnancy is rising and rates of serious adverse maternal and fetal outcomes remain high. Metformin is a biguanide that is used as first-line treatment for non-pregnant patients with type 2 diabetes. We hypothesize that metformin use in pregnancy, as an adjunct to insulin, will decrease adverse outcomes by reducing maternal hyperglycemia, maternal insulin doses, maternal weight gain and gestational hypertension/pre-eclampsia. In addition, since metformin cr…
Publication
ID26302758Published Date2015-11-19JournalBlood, 2015-11-19, Volume 126
Pregnancy in women with sickle cell disease is associated with adverse maternal and neonatal outcomes. Studies assessing the effects of prophylactic red blood cell transfusions on these outcomes have drawn inconsistent conclusions. The objective of this systematic review was to assess the effect of prophylactic compared with on-demand red blood cell transfusions on maternal and neonatal outcomes in women with sickle cell disease. A systematic search of several medical literature databases was…
Clinical Trial
Clinical Trial IDNCT02400021Start Date2015-08-01Completion Date2016-12-01PhasePhase 2Study TypeInterventionalStatusUnknown status
In pregnancy, cART is considered optimal for maternal health and for preventing the emergence of resistance that could compromise further care. In Canada, the majority of HIV-positive pregnant women receive a PI-based cART regimen. In the past, therapy was generally deferred until after the first trimester (if not required for maternal health) to minimize any unknown risk of teratogenicity. However, as treatment is now started earlier in HIV infection and as perinatal transmission rates are l…
Clinical Trial
Clinical Trial IDNCT00187382Start Date2001-04-01Completion Date2011-12-01PhasePhase 4Study TypeInterventionalStatusCompleted
In women at 26 to 30 weeks gestation and who are risk for threatened early birth, who have not had their baby by 14 or more days after being given a single course of antenatal corticosteroids (ACS), do repeated courses of ACS every 14 days until 33 weeks' gestational age lower the risk of illness or death in babies compared to repeated courses of placebo. Children are assessed at 2 years and 5 years for neurodevelopmental impairment.
Publication
ID12686905Published Date2003-03-01JournalClinical obstetrics and gynecology, 2003-03-01, Volume 46
We found 8 documents that match your Search
Publications: 6
Clinical Trials: 2

Wellspring Search is the world's most comprehensive collection of enriched content about emerging and licensable technology innovations.


Already a member? Sign in